OncoMatch/Clinical Trials/NCT06964568
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Is NCT06964568 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including PD-1 inhibitor and TP regimen for esophageal carcinoma.
Treatment: PD-1 inhibitor · TP regimen — The goal of this clinical trial is to learn if concurrent chemoradiotherapy followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T3-4N0M0, TXN+M0, TXNXM1 (ONLY FOR SUPRACLAVICULAR LYMPH NODES) (8th UICC-TNM classification)
Clinical stages T3-4N0M0 or TxN+M0 or TxNxM1 (Only for supraclavicular lymph nodes) based on the 8th UICC-TNM classification
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Previously received or receiving PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1.
Cannot have received: immunotherapy against PD-1/PD-L1
Previously received or receiving PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1.
Lab requirements
Blood counts
Absolute neutrophil counts (ANC) ≥1.5×10^9/L; Hemoglobin (Hb) ≥9g/dl; Platelet (Plt) ≥100×10^9/L
Kidney function
Creatinine ≤1.5 ULN
Liver function
Total bilirubin ≤1.5 upper limit of normal (ULN); AST ≤2.5 ULN; ALT ≤2.5 ULN
Adequate organ functions Absolute neutrophil counts (ANC) ≥1.5×10^9/L; Hemoglobin (Hb) ≥9g/dl; Platelet (Plt) ≥100×10^9/L; Total bilirubin ≤1.5 upper limit of normal (ULN); Aspartate transaminase (AST) ≤2.5 ULN; Alanine aminotransferase (ALT) ≤2.5 ULN; Creatinine ≤1.5 ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06964568 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, immunotherapy against PD-1/PD-L1 disqualifies patients from enrollment.
What disease stage is eligible?
Stage T3-4N0M0 or TXN+M0 or TXNXM1 (ONLY FOR SUPRACLAVICULAR LYMPH NODES) is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages